AstraZeneca (AZN)

A Wednesday session light on trading volume and news alike ended in slight gains, with the Dow setting another fresh closing high.

Energy from the first COVID-vaccine approval in the U.S. quickly died out Monday as growing closure threats mounted.

An error in AstraZeneca's COVID-19 vaccine trial and persistent coronavirus troubles in the U.S. led investors to chase the old COVID trade Friday.

Equities rallied Monday after data showed high efficacy for an AstraZeneca (AZN) vaccine that could be more easily distributed than its peers.

Johnson & Johnson (JNJ) paused a vaccine study, and Eli Lilly (LLY) was forced to do the same on a treatment trial, hampering stocks Tuesday.

The FDA's emergency-use green light of a COVID-19 treatment helped give the major indices a lift Monday, with the Dow leading the way.

A drugmaker and an MLP promise attractive payouts to investors yearning for better yields.